Recent RPRX News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2025 09:18:50 PM
- Royalty Pharma Declares Second Quarter 2025 Dividend • GlobeNewswire Inc. • 04/21/2025 08:15:00 PM
- Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 • GlobeNewswire Inc. • 04/17/2025 08:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/11/2025 01:15:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/11/2025 12:53:01 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/11/2025 12:50:39 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 04/11/2025 12:45:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2025 08:17:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2025 08:06:02 PM
- Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors • GlobeNewswire Inc. • 04/08/2025 08:15:00 PM
- Royalty Pharma Announces Upcoming Investor Day • GlobeNewswire Inc. • 03/27/2025 12:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/05/2025 10:25:14 PM
- Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2025 09:15:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/21/2025 09:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2025 10:16:26 PM
- Form PREM14A - Preliminary proxy statements relating to merger or acquisition • Edgar (US Regulatory) • 02/13/2025 11:03:51 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/12/2025 02:20:05 PM
- Royalty Pharma Announces R&D Funding Collaboration With Biogen • GlobeNewswire Inc. • 02/12/2025 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2025 12:38:36 PM
- Royalty Pharma Reports Q4 and Full Year 2024 Results • GlobeNewswire Inc. • 02/11/2025 12:15:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/04/2025 08:45:44 PM
- Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds • GlobeNewswire Inc. • 01/29/2025 02:00:00 PM
- Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 • GlobeNewswire Inc. • 01/28/2025 09:15:21 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/17/2025 10:12:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/16/2025 10:15:38 PM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM
VAYK Corrects Major Clerical Error to Report $668K Operating Revenue for 2024 • VAYK • Apr 17, 2025 9:00 AM